Via C&EN, this news (article by by Aayushi Pratap)
Big pharma companies continue to announce big, splashy investments in the US as President Donald J. Trump threatens tariffs on pharmaceutical imports.
GSK, the British pharmaceutical company, is the latest to join the club. The company has pledged to invest $30 billion in establishing manufacturing, research, and supply chain facilities in the US over the next 5 years. The announcement came on Sept. 17, during Trump’s recent 3C&E-day visit to the UK.
The new infusion will include an initial $1.2 billion investment, which will largely go toward setting up a new artificial intelligence–driven biologics facility at GSK’s existing site in King of Prussia, Pennsylvania. The construction will begin in 2026 and will create hundreds of new jobs. When it starts, the facility will help ramp up production of its range of medicines for respiratory diseases and cancers.
...Separately, Eli Lilly and Company has announced plans to build a $5 billion manufacturing plant in Richmond, Virginia. The new site, which will be ready by 2030, will be dedicated to the production of Lilly’s portfolio of antibody-drug conjugates and monoclonal antibodies, Lilly says. The company expects that the site will create 650 new jobs.
I think that this push towards US manufacturing is clearly politically driven. I am curious to know if and how research head count will change in the United States over the next five to ten years.
The timing is interesting. If they start in 2026 with a small investment (1-2 billion), they can scale back or scrap this after the 2028 election. Meanwhile, they can pitch this as a big win for the US.
ReplyDeleteLily also committing to a plant in Houston? (https://www.fox26houston.com/news/eli-lilly-building-plant-houston)
ReplyDelete